BOLT
Price
$4.08
Change
-$0.06 (-1.45%)
Updated
Oct 22 closing price
Capitalization
7.86M
20 days until earnings call
Intraday BUY SELL Signals
XENE
Price
$36.50
Change
+$0.55 (+1.53%)
Updated
Oct 22 closing price
Capitalization
3.53B
11 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

BOLT vs XENE

BOLT vs XENE Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
BOLT vs. XENE commentary
Oct 23, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BOLT is a StrongBuy and XENE is a Buy.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for BOLT with price predictions
Oct 22, 2026

BOLT in upward trend: price rose above 50-day moving average on October 09, 2026

BOLT moved above its 50-day moving average on October 09, 2026 date and that indicates a change from a downward trend to an upward trend. In 41 of 44 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 64 of 77 cases where BOLT's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 83%.

The Momentum Indicator moved above the 0 level on October 07, 2026. You may want to consider a long position or call options on BOLT as a result. In 83 of 103 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 81%.

The Moving Average Convergence Divergence (MACD) for BOLT just turned positive on October 07, 2026. Looking at past instances where BOLT's MACD turned positive, the stock continued to rise in 41 of 46 cases over the following month. The odds of a continued upward trend are 89%.

The 10-day moving average for BOLT crossed bullishly above the 50-day moving average on October 13, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 10 of 11 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 90%.

Following a +5.50% 3-day Advance, the price is estimated to grow further. Considering data from situations where BOLT advanced for three days, in 154 of 200 cases, the price rose further within the following month. The odds of a continued upward trend are 77%.

The Aroon Indicator entered an Uptrend today. In 80 of 92 cases where BOLT Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 87%.

Bearish Trend Analysis

The 10-day RSI Indicator for BOLT moved out of overbought territory on October 14, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 12 similar instances where the indicator moved out of overbought territory. In 10 of the 12 cases, the stock moved lower in the following days. This puts the odds of a move lower at 83%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where BOLT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.

BOLT broke above its upper Bollinger Band on October 09, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 30 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 49 (best 1 - 100 worst), indicating steady price growth. BOLT’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of 55 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.622) is normal, around the industry mean (2.973). P/E Ratio (-0.247) is within average values for comparable stocks, (-1.705). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.121) among similar stocks. P/S Ratio (1.355) is also within normal values, averaging (438.009).

The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BOLT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

A.I.Advisor
a Summary for XENE with price predictions
Oct 22, 2026

XENE's MACD Histogram crosses above signal line

The Moving Average Convergence Divergence (MACD) for XENE turned positive on October 07, 2026. Looking at past instances where XENE's MACD turned positive, the stock continued to rise in 44 of 49 cases over the following month. The odds of a continued upward trend are 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where XENE's RSI Indicator exited the oversold zone, 21 of 27 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 78%.

The Momentum Indicator moved above the 0 level on October 22, 2026. You may want to consider a long position or call options on XENE as a result. In 64 of 93 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 69%.

Following a +8.30% 3-day Advance, the price is estimated to grow further. Considering data from situations where XENE advanced for three days, in 195 of 290 cases, the price rose further within the following month. The odds of a continued upward trend are 67%.

XENE may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.

The 50-day moving average for XENE moved below the 200-day moving average on October 13, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where XENE declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 68%.

The Aroon Indicator for XENE entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 11 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 64 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock slightly better than average.

The Tickeron Valuation Rating of 74 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.845) is normal, around the industry mean (2.973). P/E Ratio (-7.700) is within average values for comparable stocks, (-1.705). Projected Growth (PEG Ratio) (1.930) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.121) among similar stocks. P/S Ratio (588.235) is also within normal values, averaging (438.009).

The Tickeron Price Growth Rating for this company is 80 (best 1 - 100 worst), indicating slightly worse than average price growth. XENE’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

FUNDAMENTALS RATINGS
XENE: Fundamental Ratings
XENE
OUTLOOK RATING
1..100
75
VALUATION
overvalued / fair valued / undervalued
1..100
74
Overvalued
PROFIT vs RISK RATING
1..100
64
SMR RATING
1..100
97
PRICE GROWTH RATING
1..100
80
P/E GROWTH RATING
1..100
11
SEASONALITY SCORE
1..100
50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
BOLTXENE
RSI
ODDS (%)
Bearish Trend 1 day ago
83%
Bullish Trend 1 day ago
78%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
83%
Bearish Trend 1 day ago
81%
Momentum
ODDS (%)
Bullish Trend 1 day ago
81%
Bullish Trend 1 day ago
69%
MACD
ODDS (%)
Bullish Trend 1 day ago
89%
Bullish Trend 1 day ago
90%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
89%
Bullish Trend 1 day ago
72%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
84%
Bearish Trend 1 day ago
71%
Advances
ODDS (%)
Bullish Trend 3 days ago
77%
Bullish Trend 3 days ago
67%
Declines
ODDS (%)
Bearish Trend 1 day ago
89%
Bearish Trend 9 days ago
68%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
85%
Bullish Trend 1 day ago
67%
Aroon
ODDS (%)
Bullish Trend 1 day ago
87%
Bearish Trend 1 day ago
73%
COMPARISON
Comparison
Oct 23, 2026
Stock price -- (BOLT: $4.14 vs. XENE: $36.50)
Brand notoriety: BOLT and XENE are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: BOLT: 157% vs. XENE: 76%
Market capitalization -- BOLT: $7.86M vs. XENE: $3.53B
BOLT [@Biotechnology] is valued at $7.86M. XENE’s [@Biotechnology] market capitalization is $3.53B. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $135.64B. The average market capitalization across the [@Biotechnology] industry is $2.18B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BOLT’s FA Score shows that 1 FA rating(s) are green while XENE’s FA Score has 1 green FA rating(s).

  • BOLT’s FA Score: 1 green, 4 red.
  • XENE’s FA Score: 1 green, 4 red.
According to our system of comparison, BOLT is a better buy in the long-term than XENE.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BOLT’s TA Score shows that 7 TA indicator(s) are bullish while XENE’s TA Score has 5 bullish TA indicator(s).

  • BOLT’s TA Score: 7 bullish, 3 bearish.
  • XENE’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, BOLT is a better buy in the short-term than XENE.

Price Growth

BOLT (@Biotechnology) experienced а +2.22% price change this week, while XENE (@Biotechnology) price change was +6.32% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -1.10%. For the same industry, the average monthly price growth was -18.18%, and the average quarterly price growth was -15.20%.

Reported Earning Dates

BOLT is expected to report earnings on Nov 11, 2026.

XENE is expected to report earnings on Nov 02, 2026.

Industries' Descriptions

@Biotechnology (-1.10% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
BOLT
Daily Signal:
Gain/Loss:
XENE
Daily Signal:
Gain/Loss:
Interact to see
Advertisement

BOLT and

Correlation & Price change

A.I.dvisor tells us that BOLT and XENE have been poorly correlated (+31% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that BOLT and XENE's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BOLT
1D Price
Change %
BOLT100%
-1.45%
XENE - BOLT
31%
Poorly correlated
+1.53%
ARRY - BOLT
30%
Poorly correlated
-3.23%
NRXP - BOLT
29%
Poorly correlated
-8.75%
KRRO - BOLT
29%
Poorly correlated
+29.71%
SPRO - BOLT
28%
Poorly correlated
-3.42%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
PHM119.486.59
+5.84%
Pultegroup
DKL56.910.14
+0.25%
Delek Logistics Partners LP
TCRT3.04-0.04
-1.30%
Alaunos Therapeutics Inc.
PLBY1.10-0.03
-2.65%
Playboy Inc
LXRX1.49-0.07
-4.49%
Lexicon Pharmaceuticals